KKR and Flerie, an investment firm, agreed to invest in Coriolis Pharma, a biotechnology company. Financial terms were not disclosed. “This investment presents a pivotal growth opportunity for Coriolis to realize our strategy and vision. The ability to leverage Frontier’s collective skills and expertise will be invaluable as we revolutionize the development process of biopharmaceutical drugs. Together with a strong suite of industry advisors and KKR's global network and market knowledge, we will be able to position Coriolis for the future and move one step closer to our goal of making future therapies available to humankind efficiently and on time,” Michael Wiggenhorn, Coriolis Pharma Co-Founder.